Page 1458 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 80 Clinical Manifestations, Staging, and Treatment of Follicular Lymphoma 1297.e1

REFERENCES 23. Mac Manus MP, Hoppe RT: Is radiotherapy curative for stage I and II
low-grade follicular lymphoma? Results of a long-term follow-up study
1. Swerdlow SH, Campo E, Harris NL, et al: WHO Classification of of patients treated at Stanford University. J Clin Oncol 14:1282, 1996.
Tumours of Haematopoietic and Lymphoid Tissues, ed 4, Lyon, 2008, 24. Hoppe RT, Kushlan P, Kaplan HS, et al: The treatment of advanced
IARC Press. stage favorable histology non-Hodgkin’s lymphoma: a preliminary
2. Sant M, Allemani C, Tereanu C, et al: Incidence of hematologic report of a randomized trial comparing single agent chemotherapy,
malignancies in Europe by morphologic subtype: results of the HAE- combination chemotherapy, and whole body irradiation. Blood 58:592,
MACARE project. Blood 116:3724, 2010. 1981.
3. Altieri A, Bermejo JL, Hemminki K: Familial risk for non-Hodgkin 25. Young RC, Longo DL, Glatstein E, et al: The treatment of indolent
lymphoma and other lymphoproliferative malignancies by histopatho- lymphomas: watchful waiting v aggressive combined modality treat-
logic subtype: the Swedish Family-Cancer Database. Blood 106:668, ment. Semin Hematol 25:11, 1988.
2005. 26. Brice P, Bastion Y, Lepage E, et al: Comparison in low-tumor-burden
4. Dave SS, Wright G, Tan B, et al: Prediction of survival in follicular follicular lymphomas between an initial no-treatment policy, pred-
lymphoma based on molecular features of tumor-infiltrating immune nimustine, or interferon alfa: a randomized study from the Groupe
cells. N Engl J Med 351:2159, 2004. d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes
5. Bosga-Bouwer AG, van Imhoff GW, Boonstra R, et al: Follicular de l’Adulte. J Clin Oncol 15:1110, 1997.
lymphoma grade 3B includes 3 cytogenetically defined subgroups with 27. Ardeshna KM, Smith P, Norton A, et al: Long-term effect of a watch
primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are and wait policy versus immediate systemic treatment for asymptomatic
mutually exclusive. Blood 101:1149, 2003. advanced-stage non-Hodgkin lymphoma: a randomised controlled trial.
6. Piccaluga PP, Califano A, Klein U, et al: Gene expression analysis Lancet 362:516, 2003.
provides a potential rationale for revising the histological grading of 28. Ardeshna KM, Qian W, Smith P, et al: Rituximab versus a watch-
follicular lymphomas. Haematologica 93:1033, 2008. and-wait approach in patients with advanced-stage, asymptomatic,
7. Campo E, Swerdlow SH, Harris NL, et al: The 2008 WHO clas- non-bulky follicular lymphoma: an open-label randomised phase 3
sification of lymphoid neoplasms and beyond: evolving concepts and trial. Lancet Oncol 15:424, 2014.
practical applications. Blood 117:5019, 2011. 29. Carreras J, Lopez-Guillermo A, Fox BC, et al: High numbers of
8. Leich E, Salaverria I, Bea S, et al: Follicular lymphomas with and tumor-infiltrating FOXP3-positive regulatory T cells are associated
without translocation t(14;18) differ in gene expression profiles and with improved overall survival in follicular lymphoma. Blood 108:2957,
genetic alterations. Blood 114:826, 2009. 2006.
9. Morin RD, Mendez-Lago M, Mungall AJ, et al: Frequent mutation of 30. Casulo C, Byrtek M, Dawson KL, et al: Early Relapse of Follicular
histone-modifying genes in non-Hodgkin lymphoma. Nature 476:298, Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin,
2011. Vincristine, and Prednisone Defines Patients at High Risk for Death:
10. Cerhan JR, Wang S, Maurer MJ, et al: Prognostic significance of host An Analysis From the National LymphoCare Study. J Clin Oncol
immune gene polymorphisms in follicular lymphoma survival. Blood 33:2516, 2015.
109:5439, 2007. 31. Friedberg JW, Huang J, Dillon H, et al: Initial therapeutic strategy in
11. Farinha P, Masoudi H, Skinnider BF, et al: Analysis of multiple bio- follicular lymphoma: an analysis from the National LymphoCare study.
markers shows that lymphoma-associated macrophage (LAM) content J Clin Oncol 24:7527a, 2006.
is an independent predictor of survival in follicular lymphoma (FL). 32. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab
Blood 106:2169, 2005. compared with CVP as first-line treatment for advanced follicular
12. Lee AM, Clear AJ, Calaminici M, et al: Number of CD4+ cells and lymphoma. Blood 105:1417, 2005.
location of forkhead box protein P3-positive cells in diagnostic follicular 33. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with
lymphoma tissue microarrays correlates with outcome. J Clin Oncol rituximab added to the combination of cyclophosphamide, doxoru-
24:5052, 2006. bicin, vincristine, and prednisone (CHOP) significantly improves
13. Horning SJ, Rosenberg SA: The natural history of initially untreated the outcome for patients with advanced-stage follicular lymphoma
low-grade non-Hodgkin’s lymphomas. N Engl J Med 311:1471, 1984. compared with therapy with CHOP alone: results of a prospective
14. Montoto S, Fitzgibbon J: Transformation of indolent B-cell lympho- randomized study of the German Low-Grade Lymphoma Study Group.
mas. J Clin Oncol 29:2011, 1827. Blood 106:3725, 2005.
15. Dreyling M, Ghielmini M, Marcus R, et al: Newly diagnosed and 34. Czuczman MS, Grillo-Lopez AJ, White CA, et al: Treatment of patients
relapsed follicular lymphoma: ESMO clinical practice guidelines for with low-grade B-cell lymphoma with the combination of chimeric
diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):vi59, 2011. anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin
16. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for Oncol 17:268, 1999.
malignant lymphoma. J Clin Oncol 25:579, 2007. 35. Sebban C, Mounier N, Brousse N, et al: Standard chemotherapy
17. Karam M, Novak L, Cyriac J, et al: Role of fluorine-18 fluoro- with interferon compared with CHOP followed by high-dose therapy
deoxyglucose positron emission tomography scan in the evaluation with autologous stem cell transplantation in untreated patients with
and follow-up of patients with low-grade lymphomas. Cancer 107:175, advanced follicular lymphoma: the GELF-94 randomized study from the
2006. Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood 108:2540,
18. Horning SJ: Natural history of and therapy for the indolent non- 2006.
Hodgkin’s lymphomas. Semin Oncol 20:75, 1993. 36. Romaguera JE, Fayad L, Rodriguez MA, et al: High rate of durable
19. Fisher RI, LeBlanc M, Press OW, et al: New treatment options have remissions after treatment of newly diagnosed aggressive mantle-
changed the survival of patients with follicular lymphoma. J Clin Oncol cell lymphoma with rituximab plus hyper-CVAD alternating with
23:8447, 2005. rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol
20. Hiddemann W, Hoster E, Buske C, et al: Rituximab is the essential 23:7013, 2005.
treatment modality that underlies the significant improvement in 37. Hochster HS, Weller E, Gasgoyne R, et al: Maintenance rituximab
short and long term outcome of patients with advanced stage follicular after CVP results in superior clinical outcome in advanced follicular
lymphoma a 10 year analysis of GLSG trials. Blood 108:147a, 2006. lymphoma (FL): results of the E1496 phase III trial from the Eastern
21. Solal-Celigny P, Roy P, Colombat P, et al: Follicular lymphoma inter- Cooperative Oncology Group and the Cancer and Leukemia Group B.
national prognostic index. Blood 104:1258, 2004. Blood 106a:349, 2005.
22. Federico M, Bellei M, Marcheselli L, et al: Follicular lymphoma 38. Ghielmini M, Schmitz SF, Cogliatti SB, et al: Prolonged treatment with
international prognostic index 2: a new prognostic index for follicular rituximab in patients with follicular lymphoma significantly increases
lymphoma developed by the international follicular lymphoma prog- event-free survival and response duration compared with the standard
nostic factor project. J Clin Oncol 27:4555, 2009. weekly x 4 schedule. Blood 103:4416, 2004.